Janssen Biotech

TALVEY

Manufacturer:

Janssen Biotech

Talvey HCPCS:

C9163

HCPCS Code Descriptor:

Injection, talquetamab-tgvs, 0.25 mg

Category:

C Code

Talvey NDCs:

57894-0470-01, 57894-0469-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Talvey:

TALVEY is an Oncology drug manufactured by Janssen Biotech and administered via the Subcutaneous route of administration. The C Code: C9163 is aligned to the drug TALVEY.

Talvey is an injection given to adults with multiple myeloma, a type of bone marrow cancer. Talvey is prescribed to patients whose cancer has resisted other forms of treatment, or who have has recurrences. Talvey works by attaching itself to both myeloma cancer cells and T cells in the immune system. This activated the T cells to attack and kill the cancer cells, thus slowing or stopping their growth.

ACCESS PRICING AND MORE BY REGISTERING

C9163 Added Date:

January 1, 2024

C9163 Effective Date:

January 1, 2024

C9163 Termination Date:

HCPCS Active

Talvey billing and coding information can be found through Janssen Biotech at the link below:
Talvey patient assistance information can be found through Janssen CarePath at the URL: https://www.janssencarepath.com/patient/talvey/cost-support
TALVEY prescribing information can be found at the link below:
Information regarding TALVEY’s side effects can be found at MedlinePlus